Table 1.
Comparison of demographics and RA clinical factors across cell type abundance phenotypes (CTAP).
| Clinical characteristics | Overall | CTAP |
p-value | |||||
|---|---|---|---|---|---|---|---|---|
| EFM | F | M | T+B | T+F | T+M | |||
|
| ||||||||
| N | 72 | 7 | 11 | 18 | 14 | 8 | 12 | |
| Age, yrs | 56.5 ±15.1 | 66.6 ±7.11 | 56.2 ±14.4 | 56.2 ±21.8 | 54.5 ±12.9 | 58.0 ±9.07 | 51.1 ±14.4 | 0.435 |
| Female, n (%) | 54 (75.0) | 6 (85.7) | 7 (63.6) | 13 (72.2) | 11 (78.6) | 6 (75.0) | 9 (75.0) | 0.963 |
| RA duration, yrs median [IQR] |
2.05 [0.10, 9.67] |
15.4 [4.90, 18.1] |
0.66 [0.12, 5.53] |
1.95 [0.04, 9.39] |
3.93 [0.47, 12.5] |
2.71 [0.36, 7.38] |
0.47 [0.02, 4.22] |
0.268 |
| DAS28-CRP3 | 4.84 ±1.39 | 4.47 ±0.71 | 4.80 ±1.46 | 4.61 ±1.34 | 4.81 ±1.34 | 5.34 ±2.56 | 5.43 ±1.49 | 0.626 |
| hsCRP, mg/L, median [IQR] |
8.40 [5.00, 21.0] |
6.00 [3.50, 7.00] |
7.00 [3.00, 12.0] |
9.46 [4.40, 20.5] |
10.0 [7.00, 37.1] |
29.0 [18.0, 61.2] |
8.25 [5.03, 34.5] |
0.351 |
| RA clinical factors differing across CTAPs | ||||||||
| Anti-CCP+, n (%) | 54 (76.1) | 6 (85.7) | 9 (81.8) | 9 (50.0) | 13 (92.9) | 7 (100.0) | 10 (83.3) | 0.041 |
| HAQ* | 1.27 ±0.65 | 1.20 ±0.55 | 1.08 ±0.55 | 1.21 ±0.62 | 1.07 ±0.47 | 1.91 ±0.76 | 1.46 ±0.74 | 0.041 |
| Patient global** | 5.75 ±2.25 | 4.83 ±1.49 | 4.82 ±1.65 | 6.03 ±2.58 | 5.12 ±2.78 | 7.75 ±1.56 | 6.55 ±1.12 | 0.031 |
| RA treatments, n (%) | ||||||||
| Glucocorticoids | 20 (27.8) | 1 (14.3) | 3 (27.3) | 4 (22.2) | 4 (28.6) | 4 (50.0) | 4 (33.3) | 0.731 |
| No DMARD | 29 (40.3) | 1 (14.3) | 4 (36.4) | 11 (61.1) | 5 (35.7) | 4 (50.0) | 4 (33.3) | 0.343 |
| MTX, no b/tsDMARD*** | 23 (31.9) | 0 (0.0) | 4 (36.4) | 5 (27.8) | 6 (42.9) | 3 (37.5) | 4 (33.3) | 0.466 |
| b/tsDMARD | 13 (18.1) | 4 (57.1) | 1 (9.1) | 1 (5.6) | 3 (21.4) | 0 (0.0) | 3 (25.0) | 0.036 |
| Any DMARD | 43 (59.7) | 6 (85.7) | 7 (63.6) | 7 (38.9) | 9 (64.3) | 4 (50.0) | 8 (66.7) | 0.343 |
Mean ±SD shown unless otherwise specified. The overall column includes two subjects who were not classified into CTAPs. Fischer’s exact test used to test for differences across CTAPs for binary variables; One-way ANOVA used for continuous variables. EFM=endothelial, fibroblast, myeloid; F=fibroblast; M=myeloid; T+B= T and B cells; T+F= T cells and fibroblasts; T+M= T and myeloid cells.
*
HAQ, Health Assessment Questionnaire: 0=no difficulty through 3=unable to do activities.
**
Patient global: 0=no RA activity through 10=worst RA activity.
***
Can be in combination with nbDMARDs.